Skip to main content

Table 1 Patient characteristics among the 96 ovarian cancer samples

From: Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer

 

N (%)

Median PFS in months (95 % CI)

P-value

All

96

18.0 (15.3–21.4)

 

Age <60

41 (43 %)

22.2 (13.7–35.4)

0.25

  > =60

55 (57 %)

17.1 (13.6–20.5)

 

Stage III

67 (70 %)

20.0 (16.3–30.0)

0.03

 IV

29 (30 %)

14.4 (12.7–19.2)

 

Residual disease 0 cm

43 (45 %)

28.9 (21.1–55.5)

<0.01

  > 0 cm

53 (55 %)

14.1 (12.1–16.5)